Skip to main content
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.

WARNINGREDOSING CAN TRIGGER PSYCHOSIS

PCP-like dissociatives can cause mania, paranoia, or psychosis that outlasts the high. High doses, redosing, and sleep loss raise the risk.

3-MeO-PCE

3-MeO-PCE molecule structure3-MeO-PCE molecule structure
3-Methoxyeticyclidine
Methoxieticyclidine
Psychoactive Class
Chemical Class

3-MeO-PCE is a dissociative hallucinogen of the arylcyclohexylamine classcitation needed and a structural analog of PCE.1 It began gaining popularity around 2010 as a grey-market research chemical, typically sold online as a legal alternative to PCP and ketamine.citation needed Its effects are reported to be qualitatively similar to those of PCE and PCP. It is considered potentially habit-forming, and its safety profile remains poorly characterized.

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~2 mg
Light3-5 mg
Moderate5-10 mg
Strong10-20 mg
Heavy20+ mg

At higher doses, the risk of adverse psychological effects increases significantly, including the potential for psychotic episodes, manic states, and delirium.

Duration

Onset30-90 minutes
Come Up60-120 minutes
Peak2-3 hours
Offset1-2 hours
After Effects4-48 hours
Total4-8 hours

Subjective Effects

Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.

Reported as a dissociative anesthetic with a qualitative character comparable to PCE and PCP.

See also: Dissociative Intensity Scale, Subjective Effects of Dissociatives

Reagent Testing

Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.

Mecke(ME)
white → yellow2 → brown1
Mandelin(MD)
yellow2 → green2
Liebermann(LB)
white → brown3 → black3
Morr(MO)
pink2 → green1
Powered by PROtestkit.eu

Pharmacology

Pharmacodynamics

3-MeO-PCE acts primarily as an NMDA receptor antagonist, binding at the PCP site with high affinity (Ki 61 nM).citation needed It also displays significant affinity for the serotonin transporter and sigma-2 receptor,1 with additional binding at the dopamine transporter, alpha-2A adrenergic receptor, histamine H2 receptor, and sigma-1 receptor.

Pharmacokinetics

There have been no studies on the pharmacokinetic profile of 3-MeO-PCE and the metabolism of 3-MeO-PCE is unknown.

Metabolitesnone documented yet

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

DepressantsPsychedelicsStimulants
Powered by TripSit

Tolerance

Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.

Full Tolerance
Sustained repeated 3-MeO-PCE use can produce tolerance across many effects, leading users to take larger doses for comparable effects.
Baseline Reset
1-2 weeks
Half Tolerance
3-7 days
Cross Tolerance

Dissociatives

Harm Potential

Addiction & Dependence

Psychological

High

3-MeO-PCE is considered highly addictive with a high potential for adverse side effects. It has been reported to be more habit-forming than other dissociatives such as ketamine, MXE, diphenidine, and ephenidine. Compulsive redosing is commonly reported, particularly when smoked or vaporized due to the abrupt onset and offset via this route. Multiple reports describe users becoming seriously addicted daily users.

Physical

Low

Cravings and withdrawal effects may occur upon sudden cessation after addiction has developed, though the specific nature and severity of withdrawal symptoms are not well documented.

Toxicity

Urinary System

Chronic heavy use may cause bladder and urinary tract problems similar to those seen with ketamine, including urinary frequency, urgency, pressure, pelvic and bladder pain, hematuria, and incontinence; however, these effects appear less severe than with ketamine due to the higher potency of 3-MeO-PCE requiring significantly smaller quantities to achieve effects.

Psychosis Risk

3-MeO-PCE has been reported to cause psychosis, delusions, and mania at a significantly higher rate than other dissociatives such as ketamine, MXE, or diphenidine. Heavy doses and repeated use substantially increase this risk. These effects typically occur during the offset of the experience but can also manifest during onset or come up. Numerous experience reports describe states of psychotic delirium, amnesia, mania, and other serious consequences following abuse of this substance.

Seizure Risk

Seizures have been reported as a potential effect, though frequency, severity, and precipitating conditions are not well documented.

History & Culture

3-MeO-PCE emerged on the online research chemical market around 2010,citation needed where it was marketed as a grey-area legal alternative to controlled dissociatives such as PCP and ketamine. The compound represents part of the broader wave of designer arylcyclohexylamines that became available

Trip Reports

Loading related reports

Preparing section content

Still loading. Refresh if this section does not appear.

Legality

International

3-MeO-PCE is not listed under the 1961 Single Convention on Narcotic Drugs. It is not listed under the 1971 Convention on Psychotropic Substances. It is not listed under the 1988 Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances.

By Country

Illegal10
Austria flagAustriaIllegal (analog/blanket ban)
Chile flagChileIllegal (analog/blanket ban)
Germany flagGermanyIllegal (analog/blanket ban)
Poland flagPolandIllegal
Singapore flagSingaporeIllegal
Sweden flagSwedenIllegal
Switzerland flagSwitzerlandIllegal
Turkey flagTurkeyIllegal
Ukraine flagUkraineIllegal
United Kingdom flagUnited KingdomIllegal
Controlled / restricted1
Finland flagFinlandRestricted

References

Source Pages

  1. Bluelight: The Big & Dandy 3-MeO-PCE Thread
  2. Bluelight: The Small and Handy 3-Me-PCE Thread
  3. Isomer Design (TiHKAL/PiHKAL)
  4. IsomerDesign: 3-MeO-PCE
  5. TripSit Factsheet: 3-MeO-PCE
  6. TripSit Factsheets
  7. Wikipedia

Citations

  1. Bryan L. Roth, Simon Gibbons, Warunya Arunotayanun, Xi-Ping Huang, Vincent Setola, Ric Treble, & Les Iversen. (March 2013). The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor. PLOS ONE, 8(3). https://doi.org/10.1371/journal.pone.005933412
  2. Advisory Council on the Misuse of Drugs (ACMD) Methoxetamine report, 2012. UK Home Office (18 October 2012). https://www.gov.uk/government/publications/advisory-council-on-the-misuse-of-drugs-acmd-methoxetamine-report-20121
  3. Neue-Psychoaktive-Substanzen-Verordnung (NPSV), BGBl. II Nr. 468/2011, as amended by BGBl. II Nr. 106/2024. ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/GeltendeFassung.wxe?Abfrage=Bundesnormen&Gesetzesnummer=200076421
  4. Neue-Psychoaktive-Substanzen-Verordnung (NPSV), BGBl. II Nr. 468/2011, as amended by BGBl. II Nr. 106/2024. ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/Dokumente/Bundesnormen/NOR40261441/II_106_2024_Anlage_II.pdf1
  5. Neue-Psychoaktive-Substanzen-Verordnung (NPSV), BGBl. II Nr. 468/2011, as amended by BGBl. II Nr. 106/2024. ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/GeltendeFassung.wxe?Abfrage=Bundesnormen&Gesetzesnummer=200076051
  6. PubChem compound record: N-Ethyl-1-(3-methoxyphenyl)cyclohexanamine, CID 57461569. pubchem.ncbi.nlm.nih.gov (n.d.). https://pubchem.ncbi.nlm.nih.gov/compound/574615691
  7. PubChem PUG-REST identity properties for CID 57461569. pubchem.ncbi.nlm.nih.gov (n.d.). https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/57461569/property/Title,IUPACName,MolecularFormula,MolecularWeight,CanonicalSMILES,InChI,InChIKey/JSON1
  8. PubChem PUG-REST synonyms for CID 57461569. pubchem.ncbi.nlm.nih.gov (n.d.). https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/57461569/synonyms/JSON12
  9. PubChem PUG-REST identity properties for parent eticyclidine/PCE. pubchem.ncbi.nlm.nih.gov (n.d.). https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/name/Eticyclidine/property/Title,IUPACName,MolecularFormula,CanonicalSMILES/JSON1
  10. Reglamento de la Ley N° 20.000, TM-014 A, Armada de Chile Directemar compilation. directemar.cl (n.d.). https://www.directemar.cl/directemar/site/docs/20170126/20170126122722/tm_014_a_actualizado_al_16_septiembre_2023.pdf1

Further Reading

  1. Substance Search: 3-MeO-PCE

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Lyrea avatar
    Step 2 · First-pass review

    A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Recent changes8 human edits · latest

Times are UTCNewest first

27 August 2026

  1. Lyrea · Updated the article

  2. Lyrea · Updated the article

  3. Lyrea · Updated the article

  4. Lyrea · Updated the article

24 January 2026

  1. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  2. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  3. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  4. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

All changes to this article · Site-wide recent changes

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 3-MeO-PCE article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.